Exact Mass: 341.2202116

Exact Mass Matches: 341.2202116

Found 348 metabolites which its exact mass value is equals to given mass value 341.2202116, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Propafenone

1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone

C21H27NO3 (341.1990832)


Propafenone is only found in individuals that have used or taken this drug. It is an antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. [PubChem]The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy. C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BC - Antiarrhythmics, class ic D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE standard compound; INTERNAL_ID 2285 D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC50=32 nM)[1]. Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC50 values of 4.9?μm and 8.6?μm, respectively[2]. Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis[3].

   

7-Acetylintermedine

[(1R,7AR)-1-(acetyloxy)-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl]methyl (2S)-2-hydroxy-2-[(1R)-1-hydroxyethyl]-3-methylbutanoic acid

C17H27NO6 (341.1838282)


7-acetylintermedine belongs to alkaloids and derivatives class of compounds. Those are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic propertiesand is also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus. 7-acetylintermedine is soluble (in water) and a very weakly acidic compound (based on its pKa). 7-acetylintermedine can be found in borage, which makes 7-acetylintermedine a potential biomarker for the consumption of this food product.

   
   

Pregnenolone carbonitrile

Pregnenolone carbonitrile; 3beta-Hydroxy-20-oxo-5-pregnene-16alpha-carbonitrile; Pregnenolone-16alpha-carbonitrile; PCN

C22H31NO2 (341.2354666)


   

7-Acetyllycopsamine

[(1R,7AR)-1-(acetyloxy)-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl]methyl (2S)-2-hydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoic acid

C17H27NO6 (341.1838282)


7-acetyllycopsamine is soluble (in water) and a very weakly acidic compound (based on its pKa). 7-acetyllycopsamine can be found in borage, which makes 7-acetyllycopsamine a potential biomarker for the consumption of this food product. CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2277

   

Pipernonaline

(2E,8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one

C21H27NO3 (341.1990832)


Pipernonaline is found in herbs and spices. Pipernonaline is an alkaloid from the fruits of Piper longum (long pepper

   

Retrofractamide D

(2E,4E,9E)-10-(2H-1,3-Benzodioxol-5-yl)-N-(2-methylpropyl)deca-2,4,9-trienimidate

C21H27NO3 (341.1990832)


Retrofractamide D is an alkaloid from Piper retrofractum (Javanese long pepper). Alkaloid from Piper retrofractum (Javanese long pepper).

   

5-Hydroxymethyl tolterodine

(R)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine

C22H31NO2 (341.2354666)


5-Hydroxymethyl tolterodine is only found in individuals that have used or taken tolterodine. 5-Hydroxymethyl tolterodine is a metabolite of tolterodine. 5-Hydroxymethyl tolterodine belongs to the family of Diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.

   

trans-2-Dodecenoylcarnitine

(4S)-4-[(2E)-Dodec-2-enoyloxy]-4-(trimethylazaniumyl)butanoic acid

C19H35NO4 (341.25659500000006)


trans-2-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an trans-2-dodecenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. trans-2-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine trans-2-dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular trans-2-dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(5-methylpyridin-2-yl)ethyl)oxalamide

N-[(2-methoxy-4-methylphenyl)methyl]-N-[2-(5-methylpyridin-2-yl)ethyl]ethanediamide

C19H23N3O3 (341.1739328)


N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(5-methylpyridin-2-yl)ethyl)oxalamide is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]")

   

3,4-Dimethylideneoctanedioylcarnitine

3-[(7-carboxy-3,4-dimethylideneheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


3,4-Dimethylideneoctanedioylcarnitine is an acylcarnitine. More specifically, it is an 3,4-dimethylideneoctanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-Dimethylideneoctanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-Dimethylideneoctanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2,3-Dimethylideneoctanedioylcarnitine

3-[(7-carboxy-2,3-dimethylideneheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


2,3-Dimethylideneoctanedioylcarnitine is an acylcarnitine. More specifically, it is an 2,3-dimethylideneoctanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2,3-Dimethylideneoctanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2,3-Dimethylideneoctanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Deca-5,8-dienedioylcarnitine

3-[(9-carboxynona-5,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


Deca-5,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an deca-5,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Deca-5,8-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Deca-5,8-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2Z,4E)-Deca-2,4-dienedioylcarnitine

3-[(9-carboxynona-2,4-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


(2Z,4E)-Deca-2,4-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (2Z,4E)-deca-2,4-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z,4E)-Deca-2,4-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z,4E)-Deca-2,4-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Deca-3,8-dienedioylcarnitine

3-[(9-carboxynona-3,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


Deca-3,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an deca-3,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Deca-3,8-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Deca-3,8-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Deca-2,8-dienedioylcarnitine

3-[(9-carboxynona-2,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


Deca-2,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an deca-2,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Deca-2,8-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Deca-2,8-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Deca-4,7-dienedioylcarnitine

3-[(9-carboxynona-4,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


Deca-4,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an deca-4,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Deca-4,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Deca-4,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Deca-5,7-dienedioylcarnitine

3-[(9-carboxynona-5,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


Deca-5,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an deca-5,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Deca-5,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Deca-5,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Deca-4,6-dienedioylcarnitine

3-[(9-carboxynona-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


Deca-4,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an deca-4,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Deca-4,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Deca-4,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Deca-4,8-dienedioylcarnitine

3-[(9-carboxynona-4,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


Deca-4,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an deca-4,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Deca-4,8-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Deca-4,8-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Deca-3,7-dienedioylcarnitine

3-[(9-carboxynona-3,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H27NO6 (341.1838282)


Deca-3,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an deca-3,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Deca-3,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Deca-3,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(9E)-Dodecenoylcarnitine

3-(dodec-9-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


(9E)-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an (9E)-dodec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9E)-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (9E)-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (9E)-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Dodecenoylcarnitine

3-(dodec-4-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


4-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an dodec-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 4-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-Dodecenoylcarnitine

3-(dodec-11-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


11-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an Dodecenoylcarnitine ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 11-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 11-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Dodecenoylcarnitine

3-(dodec-5-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


5-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an dodec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 5-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Dodecenoylcarnitine

3-(dodec-7-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


7-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an dodec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 7-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Dodecenoylcarnitine

3-(dodec-8-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


8-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an dodec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 8-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Dodecenoylcarnitine

3-(dodec-2-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


2-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an dodec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 2-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Dodecenoylcarnitine

3-(dodec-3-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


3-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an dodec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 3-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Dodecenoylcarnitine

3-(dodec-6-enoyloxy)-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


6-Dodecenoylcarnitine is an acylcarnitine. More specifically, it is an dodec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Dodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Dodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 6-Dodecenoylcarnitine is elevated in the blood or plasma of individuals with mitochondrial dysfunction in diabetes patients (PMID: 28726959) and children obesity (PMID: 23108202). It is also decreased in the blood or plasma of individuals with placental abruption (PMID: 27300725) increase in dodecanoylcarnitine/dodecenoylcarnitine (c12 / c12:1). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

1-Pentyl-3-(1-naphthoyl)indole

3-(naphthalene-1-carbonyl)-1-pentyl-1H-indole

C24H23NO (341.1779548)


   

1H-Purine-2,6-dione, 7-(2-(ethylamino)ethyl)-3,7-dihydro-1,3-dimethyl-8-(phenylmethyl)-

1H-Purine-2,6-dione, 7-(2-(ethylamino)ethyl)-3,7-dihydro-1,3-dimethyl-8-(phenylmethyl)-

C18H23N5O2 (341.1851658)


   

Diprotin A

2-({[1-(2-amino-3-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoate

C17H31N3O4 (341.23144460000003)


   

Dodecenoylcarnitine

3-Hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentadec-5-enoic acid

C19H35NO4 (341.256595)


   

Fenethylline

1,3-dimethyl-7-{2-[(1-phenylpropan-2-yl)amino]ethyl}-2,3,6,7-tetrahydro-1H-purine-2,6-dione

C18H23N5O2 (341.1851658)


N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant

   

Naloxazone

14-hydrazinylidene-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-triene-10,17-diol

C19H23N3O3 (341.1739328)


   

6-Amino-N-[6-keto-6-(6-ketohexylamino)hexyl]hexanamide

6-Amino-N-{5-[(6-oxohexyl)-C-hydroxycarbonimidoyl]pentyl}hexanimidate

C18H35N3O3 (341.267828)


   

Pregnenolone carbonitrile

14-acetyl-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-ene-13-carbonitrile

C22H31NO2 (341.2354666)


   

Tibalosin

1-(2,3-dihydro-1-benzothiophen-5-yl)-2-[(4-phenylbutyl)amino]propan-1-ol

C21H27NOS (341.18132520000006)


   

(8S,9S,10S,13S,14S,17S)-17-Acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1-carbonitrile

(8S,9S,10S,13S,14S,17S)-17-Acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1-carbonitrile

C22H31NO2 (341.2354666)


   

Acetyllycopsamine

[1-(Acetyloxy)-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl]methyl 2,3-dihydroxy-2-(propan-2-yl)butanoic acid

C17H27NO6 (341.1838282)


Acetyllycopsamine is soluble (in water) and a very weakly acidic compound (based on its pKa). Acetyllycopsamine can be found in borage, which makes acetyllycopsamine a potential biomarker for the consumption of this food product.

   

Leu-Pro-Ile

2-({[1-(2-amino-4-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

C17H31N3O4 (341.23144460000003)


   

7-Acetylechinatine

7-O-Acetylechinatine

C17H27NO6 (341.1838282)


   
   
   

Deoxycalyciphylline B

(1S,6R,7R,10R,15S,22R)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.01,6.07,15.010,14.019,22]docos-13-en-4-one

C22H31NO2 (341.2354666)


   
   
   
   
   

Malouetamide

Con-4-enine-3,18-dione

C22H31NO2 (341.2354666)


   

Daphnilactone B

(-)-Daphnilactone B

C22H31NO2 (341.2354666)


   

Deacetylheterophylloidine

Deacetylheterophylloidine

C21H27NO3 (341.1990832)


   
   
   
   

9-Methoxy-Nb-methylgeissoschizol

9-Methoxy-Nb-methylgeissoschizol

C21H29N2O2+ (341.2228914)


   

Nb-Methylisoajmaline

(+)-Nb-Methylisoajmaline

C21H29N2O2 (341.2228914)


   

JWH 073 2-methylnaphthyl analog

JWH 073 2-methylnaphthyl analog

C24H23NO (341.1779548)


   
   

JWH 018

1-naphthalenyl-(1-pentyl-1H-indol-3-yl)-methanone

C24H23NO (341.1779548)


   

FENETHYLLINE

FENETHYLLINE

C18H23N5O2 (341.1851658)


N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics > N06BA - Centrally acting sympathomimetics D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant

   

2-cyclohexyl-1-oxo-1,4-dihydro-2H-spiro[cyclohexane-1,3-isoquinoline]-4-carboxylic acid

2-cyclohexyl-1-oxo-1,4-dihydro-2H-spiro[cyclohexane-1,3-isoquinoline]-4-carboxylic acid

C21H27NO3 (341.1990832)


   
   

UR-144 N-pentanoic acid

UR-144 N-pentanoic acid

C21H27NO3 (341.1990832)


   

19-methylaminoavarone|3-Methylaminoavarone

19-methylaminoavarone|3-Methylaminoavarone

C22H31NO2 (341.2354666)


   

18-methylaminoavarone|2-Methylaminoavarone|3-methylaminoavarone

18-methylaminoavarone|2-Methylaminoavarone|3-methylaminoavarone

C22H31NO2 (341.2354666)


   
   

4-ethyl-10,14-dihydroxy-5-(1-hydroxyethyl)-11-methoxy-12-oxa-4-aza-tricyclo[9.2.1.02,5]tetradec-1-en-3-one|phyllostictine C

4-ethyl-10,14-dihydroxy-5-(1-hydroxyethyl)-11-methoxy-12-oxa-4-aza-tricyclo[9.2.1.02,5]tetradec-1-en-3-one|phyllostictine C

C17H27NO6 (341.1838282)


   
   
   

18-methylaminoarenarone

18-methylaminoarenarone

C22H31NO2 (341.2354666)


   

(E)-3,7-dimethylocta-2,6-dienyl 2-(3-methylbut-2-enylamino)benzoate|geranyl N-dimethylallylanthranilate

(E)-3,7-dimethylocta-2,6-dienyl 2-(3-methylbut-2-enylamino)benzoate|geranyl N-dimethylallylanthranilate

C22H31NO2 (341.2354666)


   
   
   
   
   
   

(2E,4E,10E)-N-isobutyl-11-(4-methoxyphenyl)undeca-2,4,10-trienamide|philippinamide

(2E,4E,10E)-N-isobutyl-11-(4-methoxyphenyl)undeca-2,4,10-trienamide|philippinamide

C22H31NO2 (341.2354666)


   
   
   

regholarrhenine|Regholarrhenine A

regholarrhenine|Regholarrhenine A

C22H31NO2 (341.2354666)


   

hydroxy-3 oxo-9 seco-9,10 conatriene-1,3,5

hydroxy-3 oxo-9 seco-9,10 conatriene-1,3,5

C22H31NO2 (341.2354666)


   

17alpha-cyanomethylestra-1,3,5(10)-triene-2,3,17-triol 2-methyl ether

17alpha-cyanomethylestra-1,3,5(10)-triene-2,3,17-triol 2-methyl ether

C21H27NO3 (341.1990832)


   

3,18-Dioxo-11??-hydroxycona-1,4-diene

3,18-Dioxo-11??-hydroxycona-1,4-diene

C21H27NO3 (341.1990832)


   
   

naphthalen-2-yl(1-(pentan-2-yl)-1H-indol-3-yl)methanone

naphthalen-2-yl(1-(pentan-2-yl)-1H-indol-3-yl)methanone

C24H23NO (341.1779548)


   

JWH 018 N-(2,2-dimethylpropyl) isomer

JWH 018 N-(2,2-dimethylpropyl) isomer

C24H23NO (341.1779548)


   

JWH 018 2-naphthyl-N-(2,2-dimethylpropyl) isomer

JWH 018 2-naphthyl-N-(2,2-dimethylpropyl) isomer

C24H23NO (341.1779548)


   
   

JWH 018 N-(2-methylbutyl) isomer

JWH 018 N-(2-methylbutyl) isomer

C24H23NO (341.1779548)


   

CAY10580

2-(3-hydroxyoctyl)-5-oxo-1-pyrrolidineheptanoic acid

C19H35NO4 (341.25659500000006)


   

JWH 018 N-(1,1-dimethylpropyl) isomer

JWH 018 N-(1,1-dimethylpropyl) isomer

C24H23NO (341.1779548)


   

JWH 018 N-(1,2-dimethylpropyl) isomer

JWH 018 N-(1,2-dimethylpropyl) isomer

C24H23NO (341.1779548)


   

Acetyllycopsamine

BUTANOIC ACID, 2,3-DIHYDROXY-2-(1-METHYLETHYL)-, (1-(ACETYLOXY)-2,3,5,7A-TETRAHYDRO-1H-PYRROLIZIN-7-YL)METHYL ESTER, (1R-(1.ALPHA.,7(2S*,3S*),7A.BETA.))-

C17H27NO6 (341.1838282)


Acetyllycopsamine is a member of pyrrolizines. 7-Acetyllycopsamine is a natural product found in Echium horridum, Amsinckia menziesii, and other organisms with data available. See also: Comfrey Leaf (part of).

   

Acetylintermedine

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (1-(acetyloxy)-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl)methyl ester, (1R-(1alpha,7(2S*,3R*),7abeta))-

C17H27NO6 (341.1838282)


Acetylintermedine is a member of pyrrolizines. Acetylintermedine is a natural product found in Echium pininana, Oreocarya flava, and other organisms with data available.

   

JWH-018

1-Pentyl-3-(1-naphthoyl)indole

C24H23NO (341.1779548)


CONFIDENCE standard compound; INTERNAL_ID 1706

   

MLS002207185-01!Ile-Pro-Ile90614-48-5

MLS002207185-01!Ile-Pro-Ile90614-48-5

C17H31N3O4 (341.23144460000003)


   

(2E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,8-dien-1-one

NCGC00347382-02!(2E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,8-dien-1-one

C21H27NO3 (341.1990832)


   

Pipernonaline

(2E,8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one

C21H27NO3 (341.1990832)


   

propafenone

propafenone

C21H27NO3 (341.1990832)


C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BC - Antiarrhythmics, class ic D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC50=32 nM)[1]. Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC50 values of 4.9?μm and 8.6?μm, respectively[2]. Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis[3].

   

omega-6-undecenyltyrazolone

omega-6-undecenyltyrazolone

C21H27NO3 (341.1990832)


   

pipernonaline_major

pipernonaline_major

C21H27NO3 (341.1990832)


   

p-Hydroxynorpropoxyphene

p-Hydroxynorpropoxyphene

C21H27NO3 (341.1990832)


   

12-Hydroxyergometrine

12-Hydroxyergometrine

C19H23N3O3 (341.1739328)


   

Hydroxyergometrine M2

Hydroxyergometrine M2

C19H23N3O3 (341.1739328)


   

Hydroxyergometrine M3

Hydroxyergometrine M3

C19H23N3O3 (341.1739328)


   

(4R,6R,6S,7S,8R)-6-(2-hydroxypentan-2-yl)-4,8-dimethyldecahydro-5H-spiro[indolizine-6,2-pyran]-7,8-diol

(4R,6R,6S,7S,8R)-6-(2-hydroxypentan-2-yl)-4,8-dimethyldecahydro-5H-spiro[indolizine-6,2-pyran]-7,8-diol

C19H35NO4 (341.25659500000006)


   

PC(O-6:0/0:0)[U]

3,5,9-Trioxa-4-phosphapentadecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (1)-

C14H32NO6P (341.19671420000003)


   

Diprotin A

Diprotin A

C17H31N3O4 (341.23144460000003)


D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Diprotin A (Ile-Pro-Ile) is an inhibitor of dipeptidyl peptidase IV (DPP-IV)[1].

   

JWH 073 3-methylbutyl homolog

N-(3-Methylbutyl)-3-(1-naphthoyl)-indole

C24H23NO (341.1779548)


   

5-Hydroxymethyltolterodine

5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)

C22H31NO2 (341.2354666)


Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively[1]. Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053)[2][3]. Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats[4].

   
   

N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(5-methylpyridin-2-yl)ethyl)oxalamide

N-[(2-methoxy-4-methylphenyl)methyl]-N-[2-(5-methylpyridin-2-yl)ethyl]ethanediamide

C19H23N3O3 (341.1739328)


   

Retrofractamide D

(2E,4E,9E)-10-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)deca-2,4,9-trienamide

C21H27NO3 (341.1990832)


   
   

JWH 018 N-(1-methylbutyl) isomer

JWH 018 N-(1-methylbutyl) isomer

C24H23NO (341.1779548)


   

JWH 018 2-naphthyl-N-(3-methylbutyl) isomer

JWH 018 2-naphthyl-N-(3-methylbutyl) isomer

C24H23NO (341.1779548)


   

JWH 018 2-naphthyl-N-(1,2-dimethylpropyl) isomer

JWH 018 2-naphthyl-N-(1,2-dimethylpropyl) isomer

C24H23NO (341.1779548)


   

JWH 018 2-naphthyl-N-(1,1-dimethylpropyl) isomer

JWH 018 2-naphthyl-N-(1,1-dimethylpropyl) isomer

C24H23NO (341.1779548)


   

JWH 018 2-naphthyl-N-(1-methylbutyl) isomer

JWH 018 2-naphthyl-N-(1-methylbutyl) isomer

C24H23NO (341.1779548)


   

JWH 018 2-naphthyl-N-(2-methylbutyl) isomer

JWH 018 2-naphthyl-N-(2-methylbutyl) isomer

C24H23NO (341.1779548)


   

JWH 073 4-methylnaphthyl analog

JWH 073 4-methylnaphthyl analog

C24H23NO (341.1779548)


   

CAR 12:1

3-[(5Z)-dodecenoyloxy]-4-(trimethylazaniumyl)butanoate

C19H35NO4 (341.25659500000006)


   

d-erythro-sphingosine (sulfate)

d-erythro-sphingosine (sulfate)

C14H31NO6S (341.1871986)


   

(Rac)-5-Hydroxymethyl Tolterodine

(Rac)-5-Hydroxymethyl Tolterodine

C22H31NO2 (341.2354666)


(Rac)-5-Hydroxymethyl Tolterodine ((Rac)-Desfesoterodine), an active metabolite of Tolterodine, is a mAChR antagonist (Ki values of 2.3 nM, 2 nM, 2.5 nM, 2.8 nM, and 2.9 nM for M1, M2, M3, M4, and M5 receptors, respectively). (Rac)-5-Hydroxymethyl Tolterodine can be used for overactive bladder research[1].

   

Benaprizine

Benaprizine

C21H27NO3 (341.1990832)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

1-BOC-4-([3-(MORPHOLIN-4-YL)-PROPYLAMINO]-METHYL)-PIPERIDINE

1-BOC-4-([3-(MORPHOLIN-4-YL)-PROPYLAMINO]-METHYL)-PIPERIDINE

C18H35N3O3 (341.267828)


   

(E)-16-(carboxymethylamino)-4-oxohexadec-11-enoic acid

(E)-16-(carboxymethylamino)-4-oxohexadec-11-enoic acid

C18H31NO5 (341.2202116)


   

4-[3-(1-Imidazolyl)proplyaminomethyl]benzeneboronic acid pinacol ester

4-[3-(1-Imidazolyl)proplyaminomethyl]benzeneboronic acid pinacol ester

C19H28BN3O2 (341.2274458)


   

(1S,2S,5R)-3-BOC-2-[(TERT-BUTYLDIMETHYLSILYLOXY)METHYL]-4-OXO-3-AZABICYCLO[3.1.0]HEXANE

(1S,2S,5R)-3-BOC-2-[(TERT-BUTYLDIMETHYLSILYLOXY)METHYL]-4-OXO-3-AZABICYCLO[3.1.0]HEXANE

C17H31NO4Si (341.20222459999997)


   

polyamide 6 hplc 0.005-0.020mm (5-20um)&

polyamide 6 hplc 0.005-0.020mm (5-20um)&

C18H35N3O3 (341.267828)


   

coluracetam

coluracetam

C19H23N3O3 (341.1739328)


Coluracetam (MKC-231) is a new choline absorption enhancer.

   

9-ethyl-3-(n-ethyl-n-phenylhydrazonomethyl)carbazole

9-ethyl-3-(n-ethyl-n-phenylhydrazonomethyl)carbazole

C23H23N3 (341.1891878)


   

(3-chloro-2-hydroxypropyl)dodecyldimethylammonium chloride

(3-chloro-2-hydroxypropyl)dodecyldimethylammonium chloride

C17H37Cl2NO (341.2252052)


   

diethyl 2-(1-(tert-butoxycarbonyl)piperidin-4-ylidene)Malonate

diethyl 2-(1-(tert-butoxycarbonyl)piperidin-4-ylidene)Malonate

C17H27NO6 (341.1838282)


   
   
   
   

2,6-bis[1-(2-methylphenylimino)ethyl]pyridine

2,6-bis[1-(2-methylphenylimino)ethyl]pyridine

C23H23N3 (341.1891878)


   

2-di-t-butylphosphino-2-(n,n-dimethylamino)biphenyl

2-di-t-butylphosphino-2-(n,n-dimethylamino)biphenyl

C22H32NP (341.2272242)


   
   
   

N-(4-Methoxybenzyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine

N-(4-Methoxybenzyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine

C18H24BN3O3 (341.19106239999996)


   

N-(2-aminoethyl)ethane-1,2-diamine,2-(chloromethyl)oxirane,hexanedioic acid

N-(2-aminoethyl)ethane-1,2-diamine,2-(chloromethyl)oxirane,hexanedioic acid

C13H28ClN3O5 (341.1717388)


   
   

n-(1-Adamantyl)-n-(4-guanidinobenzyl)urea

n-(1-Adamantyl)-n-(4-guanidinobenzyl)urea

C19H27N5O (341.22154919999997)


   

1-(2,3-Dihydro-1-benzothiophen-5-yl)-2-(4-phenylbutylamino)propan-1-ol

1-(2,3-Dihydro-1-benzothiophen-5-yl)-2-(4-phenylbutylamino)propan-1-ol

C21H27NOS (341.18132520000006)


   

17-acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-16-carbonitrile

17-acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-16-carbonitrile

C22H31NO2 (341.2354666)


   
   

JWH 018 N-(3-methylbutyl) isomer

JWH 018 N-(3-methylbutyl) isomer

C24H23NO (341.1779548)


   

5-[3-(Dimethylamino)propylamino]-3,10-dimethylpyrimido[4,5-b]quinoline-2,4-dione

5-[3-(Dimethylamino)propylamino]-3,10-dimethylpyrimido[4,5-b]quinoline-2,4-dione

C18H23N5O2 (341.1851658)


   

1-(2-(4-Hydroxyphenoxy)ethyl)-4-((4-methylphenyl)methyl)-4-piperidinol

1-(2-(4-Hydroxyphenoxy)ethyl)-4-((4-methylphenyl)methyl)-4-piperidinol

C21H27NO3 (341.1990832)


   

3,5-diethyl-2-(3-hydroxypropylamino)-5-methyl-6H-benzo[h]quinazolin-4-one

3,5-diethyl-2-(3-hydroxypropylamino)-5-methyl-6H-benzo[h]quinazolin-4-one

C20H27N3O2 (341.2103162)


   

Diethylaminoethyl diphenylhydroxypropionate

Diethylaminoethyl diphenylhydroxypropionate

C21H27NO3 (341.1990832)


   

Desfesoterodine

5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)

C22H31NO2 (341.2354666)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively[1]. Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053)[2][3]. Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats[4].

   

9-Butyl-8-(2,5-dimethoxy-benzyl)-9H-purin-6-ylamine

9-Butyl-8-(2,5-dimethoxy-benzyl)-9H-purin-6-ylamine

C18H23N5O2 (341.1851658)


   

2-{[1-(2-Amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoic acid

2-{[1-(2-Amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoic acid

C17H31N3O4 (341.23144460000003)


   

7-[2-(3-Hydroxyoctyl)-5-oxopyrrolidin-1-YL]heptanoic acid

7-[2-(3-Hydroxyoctyl)-5-oxopyrrolidin-1-YL]heptanoic acid

C19H35NO4 (341.25659500000006)


   

3-Hydroxyquininium

3-Hydroxyquininium

C20H25N2O3+ (341.186508)


An organic cation that is the conjugate acid of 3-hydroxyquinine, formed via protonation of the tertiary amino group; major species at pH 7.3.

   

3-Oxo-23,24-bisnorchola-1,4-dien-22-oate(1-)

3-Oxo-23,24-bisnorchola-1,4-dien-22-oate(1-)

C22H29O3- (341.21165840000003)


   

3-Carbamoyl-2-tetradecanamidopropanoate

3-Carbamoyl-2-tetradecanamidopropanoate

C18H33N2O4- (341.24401980000005)


   
   

2-hydroxy-6-[(8Z,11Z)-pentadeca-8,11,14-trienyl]benzoate

2-hydroxy-6-[(8Z,11Z)-pentadeca-8,11,14-trienyl]benzoate

C22H29O3- (341.21165840000003)


   

(7Z)-7-hydrazinylidene-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol

(7Z)-7-hydrazinylidene-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol

C19H23N3O3 (341.1739328)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids

   

(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentadec-5-enoate

(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentadec-5-enoate

C19H35NO4 (341.25659500000006)


   

3,4-Dimethylideneoctanedioylcarnitine

3,4-Dimethylideneoctanedioylcarnitine

C17H27NO6 (341.1838282)


   

2,3-Dimethylideneoctanedioylcarnitine

2,3-Dimethylideneoctanedioylcarnitine

C17H27NO6 (341.1838282)


   
   
   
   
   
   
   
   
   

Deca-5,8-dienedioylcarnitine

Deca-5,8-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

Deca-3,8-dienedioylcarnitine

Deca-3,8-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

Deca-2,8-dienedioylcarnitine

Deca-2,8-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

Deca-4,7-dienedioylcarnitine

Deca-4,7-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

Deca-5,7-dienedioylcarnitine

Deca-5,7-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

Deca-4,6-dienedioylcarnitine

Deca-4,6-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

Deca-4,8-dienedioylcarnitine

Deca-4,8-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

Deca-3,7-dienedioylcarnitine

Deca-3,7-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

(2Z,4E)-Deca-2,4-dienedioylcarnitine

(2Z,4E)-Deca-2,4-dienedioylcarnitine

C17H27NO6 (341.1838282)


   

14-oxo-DoHE(1-)

14-oxo-DoHE(1-)

C22H29O3- (341.21165840000003)


A polyunsaturated hydroxy-fatty acid anion that is the conjugate base of 14-oxo-DoHE, arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

N-(3,4-dimethylphenyl)-3-[(4-fluorophenyl)methyl]-1,3-diazinane-1-carboxamide

N-(3,4-dimethylphenyl)-3-[(4-fluorophenyl)methyl]-1,3-diazinane-1-carboxamide

C20H24FN3O (341.1903306)


   

3-(4-ethoxyphenyl)-N-[(1-methyl-4-piperidinylidene)amino]-1H-pyrazole-5-carboxamide

3-(4-ethoxyphenyl)-N-[(1-methyl-4-piperidinylidene)amino]-1H-pyrazole-5-carboxamide

C18H23N5O2 (341.1851658)


   

(13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate

(13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate

C22H29O3- (341.21165840000003)


A polyunsaturated fatty acid anion that is the conjugate base of 13S,14S-epoxy-DHA, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

2-methoxy-6-((E)-{[4-(2-methoxyphenyl)-1-piperazinyl]imino}methyl)phenol

2-methoxy-6-((E)-{[4-(2-methoxyphenyl)-1-piperazinyl]imino}methyl)phenol

C19H23N3O3 (341.1739328)


   

(9S,10E,12Z,14E,16S)-9,16-bis(hydroperoxy)octadecatrienoate

(9S,10E,12Z,14E,16S)-9,16-bis(hydroperoxy)octadecatrienoate

C18H29O6- (341.1964034)


   

S-12-hydroxyfarnesyl-L-cysteine

S-12-hydroxyfarnesyl-L-cysteine

C18H31NO3S (341.2024536)


   
   

1-(2-Furanyl)-2-(3-heptyl-2-imino-1-benzimidazolyl)ethanol

1-(2-Furanyl)-2-(3-heptyl-2-imino-1-benzimidazolyl)ethanol

C20H27N3O2 (341.2103162)


   

1-(4-Ethoxyphenyl)-3-(4-morpholinyl)-2-phenyl-1-propanol

1-(4-Ethoxyphenyl)-3-(4-morpholinyl)-2-phenyl-1-propanol

C21H27NO3 (341.1990832)


   

1-(2,3-Dimethylphenoxy)-3-[4-(2-pyridinyl)-1-piperazinyl]-2-propanol

1-(2,3-Dimethylphenoxy)-3-[4-(2-pyridinyl)-1-piperazinyl]-2-propanol

C20H27N3O2 (341.2103162)


   

(1R,5S)-3-(phenylmethyl)-7-(4-pyridin-4-ylphenyl)-3,6-diazabicyclo[3.1.1]heptane

(1R,5S)-3-(phenylmethyl)-7-(4-pyridin-4-ylphenyl)-3,6-diazabicyclo[3.1.1]heptane

C23H23N3 (341.1891878)


   

(1R,5S)-7-(4-phenylphenyl)-3-(3-pyridinylmethyl)-3,6-diazabicyclo[3.1.1]heptane

(1R,5S)-7-(4-phenylphenyl)-3-(3-pyridinylmethyl)-3,6-diazabicyclo[3.1.1]heptane

C23H23N3 (341.1891878)


   

1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.23144460000003)


   

1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.23144460000003)


   

1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.23144460000003)


   

1-[(1S,2aR,8bR)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-1-butanone

1-[(1S,2aR,8bR)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-1-butanone

C19H23N3O3 (341.1739328)


   

2-morpholin-4-yl-1-[(1R,5S)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]ethanone

2-morpholin-4-yl-1-[(1R,5S)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]ethanone

C20H27N3O2 (341.2103162)


   

1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.23144460000003)


   

1-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.23144460000003)


   

1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea

C17H31N3O4 (341.23144460000003)


   

1-[(1R,2aS,8bS)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-1-butanone

1-[(1R,2aS,8bS)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-1-butanone

C19H23N3O3 (341.1739328)


   

O-[(5Z)-dodecenoyl]carnitine

O-[(5Z)-dodecenoyl]carnitine

C19H35NO4 (341.25659500000006)


An O-dodecenoylcarnitine having (5Z)-dodecenoyl as the acyl substituent.

   
   
   

(4Z,7Z,10Z,14E,16Z,19Z)-13-oxodocosa-4,7,10,14,16,19-hexaenoate

(4Z,7Z,10Z,14E,16Z,19Z)-13-oxodocosa-4,7,10,14,16,19-hexaenoate

C22H29O3- (341.21165840000003)


   

6-tert-butyl-N-[(E)-(1-methylpyrrol-2-yl)methylideneamino]-2,3-dihydro-1,4-benzodioxine-3-carboxamide

6-tert-butyl-N-[(E)-(1-methylpyrrol-2-yl)methylideneamino]-2,3-dihydro-1,4-benzodioxine-3-carboxamide

C19H23N3O3 (341.1739328)


   

(4Z,7Z,10Z,12E,14E)-15-{(2S,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,12,14-pentaenoate

(4Z,7Z,10Z,12E,14E)-15-{(2S,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,12,14-pentaenoate

C22H29O3- (341.21165840000003)


   

(4Z,7Z,10Z,13Z)-15-{(3R)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-ylidene}pentadeca-4,7,10,13-tetraenoate

(4Z,7Z,10Z,13Z)-15-{(3R)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-ylidene}pentadeca-4,7,10,13-tetraenoate

C22H29O3- (341.21165840000003)


   

(3-Hexoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(3-Hexoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C14H32NO6P (341.19671420000003)


   

2-Aminoethyl (2-hydroxy-3-nonoxypropyl) hydrogen phosphate

2-Aminoethyl (2-hydroxy-3-nonoxypropyl) hydrogen phosphate

C14H32NO6P (341.19671420000003)


   

2-(2-Butenoxy)-N-(2-diethylaminoethyl)-4-quinolinecarboxamide

2-(2-Butenoxy)-N-(2-diethylaminoethyl)-4-quinolinecarboxamide

C20H27N3O2 (341.2103162)


   
   

methylglyoxal-lysine dimer

methylglyoxal-lysine dimer

C16H29N4O4 (341.2188694)


An imidazolium ion formed via cyclo-dimerisation of L-lysine and methylglyoxal.

   

(4Z,8E,10Z,13Z,16Z,19Z)-7-oxodocosahexaenoate

(4Z,8E,10Z,13Z,16Z,19Z)-7-oxodocosahexaenoate

C22H29O3 (341.21165840000003)


An oxodocosahexaenoate that is the conjugate base of (4Z,8E,10Z,13Z,16Z,19Z)-7-oxodocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,15E,19Z)-17-oxodocosahexaenoate

(4Z,7Z,10Z,13Z,15E,19Z)-17-oxodocosahexaenoate

C22H29O3 (341.21165840000003)


An oxodocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,13Z,15E,19Z)-17-oxodocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(16S,17S)-epoxy-(4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoate

(16S,17S)-epoxy-(4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoate

C22H29O3 (341.21165840000003)


A docosanoid anion that is the conjugate base of (16S,17S)-epoxy-(4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

O-dodecenoylcarnitine

O-dodecenoylcarnitine

C19H35NO4 (341.25659500000006)


An O-acylcarnitine in which the acyl group specified is dodecenoyl.

   

O-dodecenoyl-L-carnitine

O-dodecenoyl-L-carnitine

C19H35NO4 (341.25659500000006)


An O-acyl-L-carnitine that is L-carnitine having dodecenoyl group as the acyl substituent in which the position of the double bond is unspecified.

   

(4Z,7Z,10Z,14E,16Z,19Z)-13-oxodocosahexaenoate

(4Z,7Z,10Z,14E,16Z,19Z)-13-oxodocosahexaenoate

C22H29O3 (341.21165840000003)


An oxodocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,14E,16Z,19Z)-13-oxodocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   
   
   
   

CB2R/FAAH modulator-3

CB2R/FAAH modulator-3

C22H31NO2 (341.2354666)


CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The Ki values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC50 value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection[1].

   

(1s,7s,10s,11r,15r,22r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one

(1s,7s,10s,11r,15r,22r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one

C22H31NO2 (341.2354666)


   

(1s,2r,3r,5s,8r,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

(1s,2r,3r,5s,8r,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

C22H31NO2 (341.2354666)


   

(1e,5r,10s,11s,14s)-4-ethyl-10,14-dihydroxy-5-[(1s)-1-hydroxyethyl]-11-methoxy-12-oxa-4-azatricyclo[9.2.1.0²,⁵]tetradec-1-en-3-one

(1e,5r,10s,11s,14s)-4-ethyl-10,14-dihydroxy-5-[(1s)-1-hydroxyethyl]-11-methoxy-12-oxa-4-azatricyclo[9.2.1.0²,⁵]tetradec-1-en-3-one

C17H27NO6 (341.1838282)


   

(1s,2s,5s,6r,9r,11r,12s,13s)-8,11-dihydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,14,17-trien-16-one

(1s,2s,5s,6r,9r,11r,12s,13s)-8,11-dihydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,14,17-trien-16-one

C21H27NO3 (341.1990832)


   

(5z,8z,11z)-n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid

(5z,8z,11z)-n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid

C22H31NO2 (341.2354666)


   

6-hydroxy-7-(2-methylpropyl)-4-(2-methylpropylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one

6-hydroxy-7-(2-methylpropyl)-4-(2-methylpropylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one

C19H23N3O3 (341.1739328)


   

(1s,2s,3r,5r,6s,10s,16s)-16-hydroxy-2,6-dimethyl-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-13(19)-ene-14,20-dione

(1s,2s,3r,5r,6s,10s,16s)-16-hydroxy-2,6-dimethyl-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-13(19)-ene-14,20-dione

C21H27NO3 (341.1990832)


   

[(7r)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

[(7r)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C17H27NO6 (341.1838282)


   

(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate

(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate

C17H27NO6 (341.1838282)


   

(1s,6r,7s,10r,15r,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6r,7s,10r,15r,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2354666)


   

(1s,4s,7s,9r)-6,9-dihydroxy-4-methyl-1-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

(1s,4s,7s,9r)-6,9-dihydroxy-4-methyl-1-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C19H23N3O3 (341.1739328)


   

(1r,7r,10r,11s,15s,18s,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

(1r,7r,10r,11s,15s,18s,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

C22H31NO2 (341.2354666)


   

16-hydroxy-2,6-dimethyl-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-13(19)-ene-14,20-dione

16-hydroxy-2,6-dimethyl-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-13(19)-ene-14,20-dione

C21H27NO3 (341.1990832)


   

(2s,3r,4s,5s)-3,6-diamino-4-{[(2r,5s)-5-amino-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexane-1,2,5-triol

(2s,3r,4s,5s)-3,6-diamino-4-{[(2r,5s)-5-amino-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexane-1,2,5-triol

C12H27N3O8 (341.1798062)


   

[(7s,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

[(7s,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C17H27NO6 (341.1838282)


   

(4z,7s)-6-hydroxy-7-(2-methylpropyl)-4-(2-methylpropylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one

(4z,7s)-6-hydroxy-7-(2-methylpropyl)-4-(2-methylpropylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one

C19H23N3O3 (341.1739328)


   

3,18-dioxo-11α-hydroxycona-1,4-diene

NA

C21H27NO3 (341.1990832)


{"Ingredient_id": "HBIN006971","Ingredient_name": "3,18-dioxo-11\u03b1-hydroxycona-1,4-diene","Alias": "NA","Ingredient_formula": "C21H27NO3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6468","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

3'-acetylechinatine

NA

C17H27NO6 (341.1838282)


{"Ingredient_id": "HBIN007876","Ingredient_name": "3'-acetylechinatine","Alias": "NA","Ingredient_formula": "C17H27NO6","Ingredient_Smile": "CC(C)C(C(C)OC(=O)C)(C(=O)OCC1=CCN2C1C(CC2)O)O","Ingredient_weight": "341.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "37200","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101924036","DrugBank_id": "NA"}

   

3'-acetylrinderine

NA

C17H27NO6 (341.1838282)


{"Ingredient_id": "HBIN007882","Ingredient_name": "3'-acetylrinderine","Alias": "NA","Ingredient_formula": "C17H27NO6","Ingredient_Smile": "CC(C)C(C(C)OC(=O)C)(C(=O)OCC1=CCN2C1C(CC2)O)O","Ingredient_weight": "341.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "37198","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101993113","DrugBank_id": "NA"}

   

7-Acetyllycops-amine

NA

C17H27NO6 (341.1838282)


{"Ingredient_id": "HBIN013023","Ingredient_name": "7-Acetyllycops-amine","Alias": "NA","Ingredient_formula": "C17H27NO6","Ingredient_Smile": "CC(C)C(C(C)O)(C(=O)OCC1=CCN2C1C(CC2)OC(=O)C)O","Ingredient_weight": "341.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "37733","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "91747347","DrugBank_id": "NA"}

   

acetylindicine

NA

C17H27NO6 (341.1838282)


{"Ingredient_id": "HBIN014477","Ingredient_name": "acetylindicine","Alias": "NA","Ingredient_formula": "C17H27NO6","Ingredient_Smile": "CC(C)C(C(C)OC(=O)C)(C(=O)OCC1=CCN2C1C(CC2)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "437","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(3s,6s)-3-({1-[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]indol-3-yl}methyl)-6-methyl-3,6-dihydropyrazine-2,5-diol

(3s,6s)-3-({1-[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]indol-3-yl}methyl)-6-methyl-3,6-dihydropyrazine-2,5-diol

C19H23N3O3 (341.1739328)


   

(1s,5r,8r,9s,11s,13s,14s,17r,18s)-13-hydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10-dione

(1s,5r,8r,9s,11s,13s,14s,17r,18s)-13-hydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10-dione

C21H27NO3 (341.1990832)


   

(2s,3s)-2-({[(2s)-1-[(2s,3s)-2-amino-3-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

(2s,3s)-2-({[(2s)-1-[(2s,3s)-2-amino-3-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

C17H31N3O4 (341.23144460000003)


   

(2r,3z,12bs)-3-ethylidene-2-(2-hydroxyethyl)-9-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

(2r,3z,12bs)-3-ethylidene-2-(2-hydroxyethyl)-9-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

[C21H29N2O2]+ (341.2228914)


   

(4'r,6r,6's,7s,8r,8as)-6'-[(2r)-2-hydroxypentan-2-yl]-4',8-dimethyl-hexahydrospiro[indolizine-6,2'-oxane]-7,8-diol

(4'r,6r,6's,7s,8r,8as)-6'-[(2r)-2-hydroxypentan-2-yl]-4',8-dimethyl-hexahydrospiro[indolizine-6,2'-oxane]-7,8-diol

C19H35NO4 (341.25659500000006)


   

11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

C22H31NO2 (341.2354666)


   

(2e,4e,10e)-11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

(2e,4e,10e)-11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

C22H31NO2 (341.2354666)


   

10-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)deca-2,4,9-trienimidic acid

10-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)deca-2,4,9-trienimidic acid

C21H27NO3 (341.1990832)


   

(1s,6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2354666)


   

6,9-dihydroxy-4-methyl-1-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

6,9-dihydroxy-4-methyl-1-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C19H23N3O3 (341.1739328)


   

(1r,7r,10r,11s,15s,18r,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

(1r,7r,10r,11s,15s,18r,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

C22H31NO2 (341.2354666)


   

(1r,3s,5r,8r,9s,11s,14r,17r,18r)-3-hydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

(1r,3s,5r,8r,9s,11s,14r,17r,18r)-3-hydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

C21H27NO3 (341.1990832)


   

n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid

n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid

C22H31NO2 (341.2354666)


   

(1s,2s,3s,5r,8s,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

(1s,2s,3s,5r,8s,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one

C22H31NO2 (341.2354666)


   

(1s,6s,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6s,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2354666)


   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 2-[(1r)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 2-[(1r)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C17H27NO6 (341.1838282)


   

11-hydroxy-7,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-6,16-dione

11-hydroxy-7,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-6,16-dione

C21H27NO3 (341.1990832)


   

1-{3-[(2s,6r,8r,9r,11s,13s)-13-(prop-2-en-1-yl)-1,7-diazatetracyclo[7.3.1.0²,⁷.0⁶,¹¹]tridecan-8-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone

1-{3-[(2s,6r,8r,9r,11s,13s)-13-(prop-2-en-1-yl)-1,7-diazatetracyclo[7.3.1.0²,⁷.0⁶,¹¹]tridecan-8-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone

C21H31N3O (341.2466996)


   

(1r,7r,10r,11r,15s,18r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

(1r,7r,10r,11r,15s,18r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

C22H31NO2 (341.2354666)


   

{7-[(2-methylbutanoyl)oxy]-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl}methyl 2,3-dihydroxybutanoate

{7-[(2-methylbutanoyl)oxy]-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl}methyl 2,3-dihydroxybutanoate

C17H27NO6 (341.1838282)


   

2-{[(1r,2s,4as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-5-(methylamino)cyclohexa-2,5-diene-1,4-dione

2-{[(1r,2s,4as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-5-(methylamino)cyclohexa-2,5-diene-1,4-dione

C22H31NO2 (341.2354666)


   

1-{3-[(2s,8r,9r,11s,13s)-13-(prop-2-en-1-yl)-1,7-diazatetracyclo[7.3.1.0²,⁷.0⁶,¹¹]tridecan-8-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone

1-{3-[(2s,8r,9r,11s,13s)-13-(prop-2-en-1-yl)-1,7-diazatetracyclo[7.3.1.0²,⁷.0⁶,¹¹]tridecan-8-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone

C21H31N3O (341.2466996)


   

(1s,2s,3r,5r,6s,10s,16r)-16-hydroxy-2,6-dimethyl-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-13(19)-ene-14,20-dione

(1s,2s,3r,5r,6s,10s,16r)-16-hydroxy-2,6-dimethyl-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-13(19)-ene-14,20-dione

C21H27NO3 (341.1990832)


   

(1s,2r,5s,6s,9r,11s,12s,13s)-8,11-dihydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,14,17-trien-16-one

(1s,2r,5s,6s,9r,11s,12s,13s)-8,11-dihydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,14,17-trien-16-one

C21H27NO3 (341.1990832)


   

(2s,3r,4s)-2-heptyl-3,4-dihydroxy-3-(hydroxymethyl)-6-methoxy-7-methylidene-2h,4h-pyrano[2,3-c]pyrrol-5-one

(2s,3r,4s)-2-heptyl-3,4-dihydroxy-3-(hydroxymethyl)-6-methoxy-7-methylidene-2h,4h-pyrano[2,3-c]pyrrol-5-one

C17H27NO6 (341.1838282)


   

6'-(2-hydroxypentan-2-yl)-4',8-dimethyl-hexahydrospiro[indolizine-6,2'-oxane]-7,8-diol

6'-(2-hydroxypentan-2-yl)-4',8-dimethyl-hexahydrospiro[indolizine-6,2'-oxane]-7,8-diol

C19H35NO4 (341.25659500000006)


   

(1s,2s,5s,6s,9r,11r,12s,13r)-11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

(1s,2s,5s,6s,9r,11r,12s,13r)-11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C22H31NO2 (341.2354666)


   

11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

C22H31NO2 (341.2354666)


   

9-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one

9-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one

C21H27NO3 (341.1990832)


   

(2e,4e,9e)-10-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)deca-2,4,9-trienimidic acid

(2e,4e,9e)-10-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)deca-2,4,9-trienimidic acid

C21H27NO3 (341.1990832)


   

8,11-dihydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,14,17-trien-16-one

8,11-dihydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,14,17-trien-16-one

C21H27NO3 (341.1990832)


   

4-ethyl-10,14-dihydroxy-5-(1-hydroxyethyl)-11-methoxy-12-oxa-4-azatricyclo[9.2.1.0²,⁵]tetradec-1-en-3-one

4-ethyl-10,14-dihydroxy-5-(1-hydroxyethyl)-11-methoxy-12-oxa-4-azatricyclo[9.2.1.0²,⁵]tetradec-1-en-3-one

C17H27NO6 (341.1838282)


   

(6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2354666)


   

13-hydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10-dione

13-hydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10-dione

C21H27NO3 (341.1990832)


   

(1s,2s,5s,9r,11r,12s,13r)-11-hydroxy-7,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-6,16-dione

(1s,2s,5s,9r,11r,12s,13r)-11-hydroxy-7,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-6,16-dione

C21H27NO3 (341.1990832)


   

11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

C22H31NO2 (341.2354666)


   

(1r,7r,10r,14s,15s,22r)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

(1r,7r,10r,14s,15s,22r)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

C22H31NO2 (341.2354666)


   

[(7r)-7-[(2-methylbutanoyl)oxy]-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 2,3-dihydroxybutanoate

[(7r)-7-[(2-methylbutanoyl)oxy]-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl 2,3-dihydroxybutanoate

C17H27NO6 (341.1838282)


   

3-{[1-(4-hydroxy-3-methylbut-2-en-1-yl)indol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol

3-{[1-(4-hydroxy-3-methylbut-2-en-1-yl)indol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol

C19H23N3O3 (341.1739328)


   

deoxyisocalyciphylline b

deoxyisocalyciphylline b

C22H31NO2 (341.2354666)


   

[(7s,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoate

[(7s,7ar)-7-(acetyloxy)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoate

C17H27NO6 (341.1838282)


   

2-heptyl-3,4-dihydroxy-3-(hydroxymethyl)-6-methoxy-7-methylidene-2h,4h-pyrano[2,3-c]pyrrol-5-one

2-heptyl-3,4-dihydroxy-3-(hydroxymethyl)-6-methoxy-7-methylidene-2h,4h-pyrano[2,3-c]pyrrol-5-one

C17H27NO6 (341.1838282)


   

(1r,7r,10r,11s,14r,15s,18r,22r,23s)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

(1r,7r,10r,11s,14r,15s,18r,22r,23s)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one

C22H31NO2 (341.2354666)


   

11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one

C22H31NO2 (341.2354666)


   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C17H27NO6 (341.1838282)


   

11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one

11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one

C22H31NO2 (341.2354666)


   

[(7r,7ar)-7-{[(2r)-2-methylbutanoyl]oxy}-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r,3s)-2,3-dihydroxybutanoate

[(7r,7ar)-7-{[(2r)-2-methylbutanoyl]oxy}-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r,3s)-2,3-dihydroxybutanoate

C17H27NO6 (341.1838282)


   

[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C17H27NO6 (341.1838282)


   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r)-2-[(1s)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C17H27NO6 (341.1838282)


   

2-({[1-(2-amino-3-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

2-({[1-(2-amino-3-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid

C17H31N3O4 (341.23144460000003)


   

(1s,5r,8r,9s,11s,13r,14s,17r,18s)-13-hydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10-dione

(1s,5r,8r,9s,11s,13r,14s,17r,18s)-13-hydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10-dione

C21H27NO3 (341.1990832)


   

(2r,3e,5s,12bs)-3-ethylidene-2-(2-hydroxyethyl)-8-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

(2r,3e,5s,12bs)-3-ethylidene-2-(2-hydroxyethyl)-8-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium

[C21H29N2O2]+ (341.2228914)


   

(1r,2s,5s,6s,9r,12s,13r)-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-17-ene-8,16-dione

(1r,2s,5s,6s,9r,12s,13r)-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-17-ene-8,16-dione

C22H31NO2 (341.2354666)


   

1-{3-[13-(prop-2-en-1-yl)-1,7-diazatetracyclo[7.3.1.0²,⁷.0⁶,¹¹]tridecan-8-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone

1-{3-[13-(prop-2-en-1-yl)-1,7-diazatetracyclo[7.3.1.0²,⁷.0⁶,¹¹]tridecan-8-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone

C21H31N3O (341.2466996)


   

(1r,4s,7s,9s)-6,9-dihydroxy-4-methyl-1-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

(1r,4s,7s,9s)-6,9-dihydroxy-4-methyl-1-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C19H23N3O3 (341.1739328)


   

[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1r)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1r)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C17H27NO6 (341.1838282)


   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1r)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-[(1r)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C17H27NO6 (341.1838282)


   

6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2354666)


   

(1s,2s,5s,6s,9r,11r,12s,13r)-8,11-dihydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,14,17-trien-16-one

(1s,2s,5s,6s,9r,11r,12s,13r)-8,11-dihydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,14,17-trien-16-one

C21H27NO3 (341.1990832)


   

(1s,6s,7r,10r,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6s,7r,10r,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO2 (341.2354666)


   

11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C22H31NO2 (341.2354666)


   

1,5-dihydroxy-3-methyl-6-{[7-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazin-2-one

1,5-dihydroxy-3-methyl-6-{[7-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazin-2-one

C19H23N3O3 (341.1739328)


   

(3s,6s)-3-(hydroxymethyl)-6-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

(3s,6s)-3-(hydroxymethyl)-6-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3,6-dihydropyrazine-2,5-diol

C19H23N3O3 (341.1739328)